Filter

Refine by Access

Refine By Collections

Refine by Type

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 11 items for :

  • "trimetazidine" x
  • All content x
Clear All

A különféle trimetazidinkészítmények klinikai hatása stabil anginával járó krónikus koszorúér-szindrómában. Frissített módszeres áttekintés és metaanalízis

Orvosi Hetilap
Volume/Issue:
Volume 161: Issue 16
DOI:
https://doi.org/10.1556/650.2020.31704
Authors: Viktor L. Nagy and Zoltán Herold

WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003; 14: 171–179. 3

Open access

Stabil coronariabetegség kezelésére alkalmazott trimetazidin prolong hatásosságának vizsgálata. Multicentrikus, prospektív, obszervációs, nyílt klinikai vizsgálat, ONECAPS-vizsgálat

Orvosi Hetilap
Volume/Issue:
Volume 159: Issue 38
DOI:
https://doi.org/10.1556/650.2018.31251
Authors: János Tomcsányi and László Szakács

, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS ONE 2012; 7: e36284. 11 Dézsi CA. Trimetazidine in practice: review of

Restricted access

Factor Optimization Study to Develop and Validate a Reversed-Phase Thin-Layer Chromatography Method for the Determination of Trimetazidine Dihydrochloride and Its Reported Impurities in Pharmaceuticals

JPC - Journal of Planar Chromatography - Modern TLC
Volume/Issue:
Volume 32: Issue 4
DOI:
https://doi.org/10.1556/1006.2019.32.4.2
Author: Suzan Mahmoud Soliman
Summary A validated reversed-phase thin-layer chromatography (RP-TLC)–densitometry method was developed and optimized for the determination of trimetazidine dihydrochloride (TMZ) and its potential impurities listed in the British Pharmacopoeia, namely, piperazinecarboxaldehyde (Y-145), trimethoxybenzyl alcohol (Y-235), and trimethoxybenzaldehyde (Y-234). Chromatographic separation was performed on aluminum plates pre-coated with silica gel 60 RP-18F using a mixture of acetonitrile–methanol–0.1% aqueous ortho-phosphoric acid pH 6.2 (4.5:4.5:1, V/V) as the developing system. Different factors affecting resolution were studied and optimized. Successful resolution was observed with significant difference in the RF values of 0.21 ± 0.02, 0.35 ± 0.02, 0.5 ± 0.02, and 0.85± 0.02 for TMZ and its impurities, respectively. Densitometric measurement was done at 215 nm over the range of 0.05–10, 0.05–1.1, 0.05–1.2, and 0.04–1.0 µg per spot with lower limits of detection (LOD) and quantification (LOQ) of 20 and 50 ng per spot for TMZ, Y-145, and Y-235, respectively, and 15 and 40 ng per spot for Y-234 impurity. Good accuracy was obtained with mean percentage recoveries of 99.55 ± 1.06, 100.50 ± 1.16, 100.07 ± 1.24, and 99.41 ± 1.11 for TMZ and its impurities, respectively. The developed method was used to investigate the impurity profile of TMZ in drug substance and different products and it was validated as per the International Conference on Harmonisation (ICH) guidelines.
Restricted access

A trimetazidin szerepe a diabeteses microangiopathia kezelésében ischaemiás szívbetegség esetén

Orvosi Hetilap
Volume/Issue:
Volume 156: Issue 19
DOI:
https://doi.org/10.1556/650.2015.30160
Authors: Zsolt Fi, Gabriella Kovács, and Veronika Szentes

Hungary: Cross-sectional study on nationally representative sample of people aged 20–69 years. Croat. Med. J., 2010, 51 (2), 151–156. 3 Dézsi, C. A.: Trimetazidine

Open access

A possible strategy for the prevention and preventive therapy of age-related macular degeneration based on recent pathophysiological and clinical observations

Clinical and Experimental Medical Journal
Volume/Issue:
Volume 3: Issue 3
DOI:
https://doi.org/10.1556/CEMED.3.2009.28524
Author: Tamás Fischer

trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus placebo trial Annales d'Oto-Larygologe et de Chirurge Cervico-Faciale 1 107Suppl 81 – 87 . [42]. R. Belardinelli M. Solenghi L. Volpe 2007

Restricted access

A new possible strategy of prevention and preventive treatment of age-related macular degeneration

Orvosi Hetilap
Volume/Issue:
Volume 149: Issue 3
DOI:
https://doi.org/10.1556/oh.2008.28237
Author: Tamás Fischer

22 797 801 Coyas, A.: The efficacy of trimetazidine in cochleovostibular disorders of ischemic origin. A crossover control versus

Restricted access

A new possible strategy for prevention and preventive treatment of age-related macular degeneration resting on recent clinical and pathophysiological observations

Orvosi Hetilap
Volume/Issue:
Volume 150: Issue 11
DOI:
https://doi.org/10.1556/oh.2009.28524
Author: Tamás Fischer

22 797 801 Coyas, A.: The efficacy of trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus

Restricted access

Adalékok az időskori maculadegeneráció – etiopatogeneziséből fakadó – gyógyszeres intervenciójához

Orvosi Hetilap
Volume/Issue:
Volume 156: Issue 46
DOI:
https://doi.org/10.1556/650.2015.30207
Author: Tamás Fischer

.: Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. Int. J. Cardiol., 2013, 167 (1), 126

Restricted access

Effect of ranolazine on cardiac microcirculation in normal and diabetic rats

Acta Physiologica Hungarica
Volume/Issue:
Volume 101: Issue 3
DOI:
https://doi.org/10.1556/APhysiol.101.2014.3.5
Authors: H. Khazraei, M. Shafa, and Hossein Mirkhani

MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH: The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93, e26

Restricted access

Evidence-based optimal treatment strategy of patients with angina pectoris

Orvosi Hetilap
Volume/Issue:
Volume 149: Issue 7
DOI:
https://doi.org/10.1556/oh.2008.28195
Author: András Jánosi

1936 Marzilli, M., Klein, W.: Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double blind, controlled trials. Coronary Artery Dis

Restricted access